kr21.70
2.12% yesterday
Stockholm, Oct 16, 05:29 pm CET
ISIN
SE0002485979
Symbol
GENO

Genovis Stock price

kr21.70
-2.35 9.77% 1M
+1.70 8.50% 6M
-3.00 12.15% YTD
-1.20 5.24% 1Y
-14.35 39.81% 3Y
-11.15 33.94% 5Y
+19.93 1,125.99% 10Y
-85.30 79.72% 20Y
Stockholm, Closing price Thu, Oct 16 2025
+0.45 2.12%

Key metrics

Basic
Market capitalization
kr1.4b
Enterprise Value
kr1.3b
Net debt
positive
Cash
kr169.0m
Shares outstanding
65.5m
Valuation (TTM | estimate)
P/E
51.8 | 55.6
P/S
11.4 | 10.0
EV/Sales
10.6 | 9.3
EV/FCF
52.6
P/B
5.8
Financial Health
Equity Ratio
69.6%
Return on Equity
14.4%
ROCE
11.7%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
kr122.0m | kr138.7m
EBITDA
kr47.3m | kr42.8m
EBIT
kr37.2m | kr31.1m
Net Income
kr27.0m | kr25.0m
Free Cash Flow
kr24.6m
Growth (TTM | estimate)
Revenue
-4.0% | 6.4%
EBITDA
35.0% | 7.4%
EBIT
60.5% | 5.6%
Net Income
56.3% | -23.9%
Free Cash Flow
-34.1%
Margin (TTM | estimate)
Gross
83.1%
EBITDA
38.8% | 30.9%
EBIT
30.5%
Net
22.1% | 18.1%
Free Cash Flow
20.1%
More
EPS
kr0.4
FCF per Share
kr0.4
Short interest
-
Employees
32
Rev per Employee
kr4.1m
Show more

Is Genovis a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Genovis Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Genovis forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Genovis forecast:

Buy
88%
Hold
13%

Financial data from Genovis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
122 122
4% 4%
100%
- Direct Costs 21 21
54% 54%
17%
101 101
24% 24%
83%
- Selling and Administrative Expenses 43 43
6% 6%
36%
- Research and Development Expense - -
-
-
47 47
35% 35%
39%
- Depreciation and Amortization 10 10
15% 15%
8%
EBIT (Operating Income) EBIT 37 37
61% 61%
31%
Net Profit 27 27
56% 56%
22%

In millions SEK.

Don't miss a Thing! We will send you all news about Genovis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Genovis AB engages in the research and development of enzyme products. Its product portfolio includes SmartEnzymes, which offers to pharmaceutical and medical device industries tools that facilitate the development of new treatment methods and diagnostics. The company was founded by Inga Sarah Maria Fredriksson in 1999 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Mr. Olsson
Employees 32
Founded 1999
Website www.genovis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today